Neurological traumas, such as spinal cord injury, and neurodegenerative disorders, such as Parkinson’s diseases, often lack effective treatment. Stem cell therapy presents a promising alternative. BrainXell has pioneered in producing highly enriched, functionally specialized neural cells from human stem cells, including cortical GABA, forebrain cholinergic, striatal medium spinal GABA, midbrain dopamine, hindbrain serotonin, spinal motor neurons, astrocytes, and oligodendrocytes.
Importantly, these cells have been tested for their therapeutic potential in animal models of neurological diseases, including Huntington’s disease, Parkinson’s disease, epilepsy, spinal cord injury, and multiple sclerosis.
We are currently examining the efficacy and safety of these cells in pre-clinical models of diseases. Meanwhile, we are building working cell banks in the GMP facility.